Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours

Documenti analoghi

• Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors
  di: Giulia Santo, et al.
  Pubblicazione: (2025)
• Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro‐entero‐pancreatic neuroendocrine neoplasms: A scoping review
  di: Raghava Kashyap, et al.
  Pubblicazione: (2024)
• Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio ( dNLR ), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy : A retrospective, cohort study of 557 patients
  di: Dimitrios Papantoniou, et al.
  Pubblicazione: (2024)
• Somatostatin receptor‐linked α‐particle therapy in neuroendocrine tumours
  di: Shaunak Navalkissoor, et al.
  Pubblicazione: (2024)
• Toxicity manifestations encountered in peptide receptor radionuclide therapy setting
  di: Rahul V. Parghane, et al.
  Pubblicazione: (2024)